PIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal ...

Patients who experience a nonaneurysmal subarachnoid hemorrhage differ from patients who suffer an aneurysmal subarachnoid hemorrhage in initial presentation (including neurological examination ...

Nxera Pharma Korea has entered into a partnership with Handok for marketing PIVLAZ 150mg in the South Korean market.

Three UNSW Sydney projects have been awarded funding under the government’s Medical Research Future Fund’s clinical trials activity initiative.UNSW Sydney researchers have been awarded more than $5.7 ...

Hyponatremia commonly occurs in patients with aneurysmal subarachnoid hemorrhage. Two mechanisms have been proposed as causes: syndrome of inappropriate anti-diuretic hormone and cerebral salt ...

PIVLAZ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage. PIVLAZ will become commercially available in South Korea ...

Researchers assessed the prevalence of occult injury in older patients with blunt head injury and how the mechanisms of injury are related to the severity of the injury.

Nxera Pharma enters exclusive supply and distribution agreement with Handok for Pivlaz in South Korea: Tokyo, Japan Tuesday, April 16, 2024, 11:00 Hrs [IST] Nxera Pharma Co. Ltd, ...

The plaintiff was rejected for the survivor pension due to being 49 years old at the time of his wife's death.

A St Albans Park dad is lucky to be alive after he suffered a rare type of stroke that is usually fatal. Father of four Bill ...

In the March 5 Nature Communications, they reported serial scans showing CSF flowing into the brain by hugging cerebral arteries in the subarachnoid space. Within minutes, the fluid seeped into ...

PIVLAZ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH)PIVLAZ will become commercially available in South ...